To include your compound in the COVID-19 Resource Center, submit it here.

Herceptin trastuzumab: Postmarketing study data

Researchers at Vall d'Hebron University Hospital reported data from an analysis of medical records from 45 patients ages 70-92 with HER2-overexpressing breast cancer who had received >=1 dose

Read the full 288 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE